Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

I0500000

Isoniazid

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

4-Pyridinecarboxylic acid hydrazide, INH, Isonicotinic acid hydrazide, Isonicotinic hydrazide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C6H7N3O
Numéro CAS:
54-85-3
Poids moléculaire :
137.14
Numéro Beilstein :
119374
Numéro MDL:
MFCD00006426
Code UNSPSC :
41116107
ID de substance PubChem :
329815311
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Agence

EP Reference Standard

Famille d'API

isoniazid

Fabricant/nom de marque

EDQM

Pf

171-173 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

NNC(=O)c1ccncc1

InChI

1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

Clé InChI

QRXWMOHMRWLFEY-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Isoniazid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Antibiotic for treatment of Mycobacterium tuberculosis, inhibits mycolic acid biosynthesis. Metabolized by hepatic N-acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins. Selectively induces expression of CYP2E1. Reversibly inhibits CYP2C19 and CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19 and CYP3A4 at clinically relevant concentrations.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H315

Classification des risques

Acute Tox. 4 Oral - Skin Irrit. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 4

1 of 4

Rifampicine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1806

Rifampicine

Pyrazinamide United States Pharmacopeia (USP) Reference Standard

USP

1585006

Pyrazinamide

Rifampicine ≥95% (HPLC), powder or crystals

Sigma-Aldrich

R3501

Rifampicine

Ethambutol dihydrochloride antimycobacterial

Sigma-Aldrich

E4630

Ethambutol dihydrochloride

Molebogeng X Rangaka et al.
Lancet (London, England), 384(9944), 682-690 (2014-05-20)
Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with
Laura Muñoz et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(3), 349-356 (2014-10-15)
The extent to which anti-tumor necrosis factor (TNF)-associated tuberculosis can be prevented is unclear, and there is no established guidance on the optimal screening strategy for latent tuberculosis (LTBI) in patients about to start anti-TNF therapy. We aimed to determine
Anandi Martin et al.
The Journal of antimicrobial chemotherapy, 62(1), 56-64 (2008-04-15)
The reference standard methods for drug susceptibility testing (DST) of M. tuberculosis are very slow to give results, and due to the emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis, there is an urgent demand for new, rapid and
Kanchan Ajbani et al.
Antimicrobial agents and chemotherapy, 59(1), 414-420 (2014-11-05)
Reliable molecular diagnostics, which detect specific mutations associated with drug resistance, are promising technologies for the rapid identification and monitoring of drug resistance in Mycobacterium tuberculosis isolates. Pyrosequencing (PSQ) has the ability to detect mutations associated with first- and second-line
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.
Dick Menzies et al.
PLoS medicine, 6(9), e1000150-e1000150 (2010-01-28)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique